PepGen (PEPG) Competitors $3.83 +0.06 (+1.59%) As of 01/3/2025 05:39 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PEPG vs. EBS, ATXS, CRMD, VERV, TERN, TBPH, RNAC, PRTC, ARCT, and ABVXShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Emergent BioSolutions (EBS), Astria Therapeutics (ATXS), CorMedix (CRMD), Verve Therapeutics (VERV), Terns Pharmaceuticals (TERN), Theravance Biopharma (TBPH), Cartesian Therapeutics (RNAC), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), and ABIVAX Société Anonyme (ABVX). These companies are all part of the "pharmaceutical preparations" industry. PepGen vs. Emergent BioSolutions Astria Therapeutics CorMedix Verve Therapeutics Terns Pharmaceuticals Theravance Biopharma Cartesian Therapeutics PureTech Health Arcturus Therapeutics ABIVAX Société Anonyme Emergent BioSolutions (NYSE:EBS) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings. Do institutionals and insiders believe in EBS or PEPG? 78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by company insiders. Comparatively, 4.6% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, EBS or PEPG? Emergent BioSolutions has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Which has stronger valuation & earnings, EBS or PEPG? PepGen has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent BioSolutions$1.09B0.51-$760.50M-$4.10-2.52PepGenN/AN/A-$78.63M-$2.98-1.29 Does the media favor EBS or PEPG? In the previous week, Emergent BioSolutions had 7 more articles in the media than PepGen. MarketBeat recorded 8 mentions for Emergent BioSolutions and 1 mentions for PepGen. Emergent BioSolutions' average media sentiment score of 0.27 beat PepGen's score of 0.18 indicating that Emergent BioSolutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent BioSolutions 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor EBS or PEPG? Emergent BioSolutions received 404 more outperform votes than PepGen when rated by MarketBeat users. However, 78.26% of users gave PepGen an outperform vote while only 66.67% of users gave Emergent BioSolutions an outperform vote. CompanyUnderperformOutperformEmergent BioSolutionsOutperform Votes42266.67% Underperform Votes21133.33% PepGenOutperform Votes1878.26% Underperform Votes521.74% Is EBS or PEPG more profitable? PepGen has a net margin of 0.00% compared to Emergent BioSolutions' net margin of -18.55%. Emergent BioSolutions' return on equity of -9.91% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets Emergent BioSolutions-18.55% -9.91% -3.31% PepGen N/A -60.17%-48.88% Do analysts recommend EBS or PEPG? Emergent BioSolutions presently has a consensus target price of $14.33, suggesting a potential upside of 38.89%. PepGen has a consensus target price of $13.67, suggesting a potential upside of 256.83%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than Emergent BioSolutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent BioSolutions 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryEmergent BioSolutions beats PepGen on 10 of the 17 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.84M$6.62B$5.21B$9.05BDividend YieldN/A2.93%4.99%4.13%P/E Ratio-1.2910.8387.7717.31Price / SalesN/A181.651,156.86124.24Price / CashN/A57.1143.2637.86Price / Book0.845.265.185.19Net Income-$78.63M$153.48M$121.70M$226.98M7 Day Performance-2.30%4.87%3.68%3.15%1 Month Performance-36.27%0.53%21.16%4.46%1 Year Performance-51.09%5.94%30.67%21.92% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.0389 of 5 stars$3.83+1.6%$13.67+256.8%-43.8%$124.84MN/A-1.2972EBSEmergent BioSolutions4.2752 of 5 stars$9.28+12.2%$14.33+54.5%+337.3%$502.83M$1.09B-2.261,600ATXSAstria Therapeutics2.8208 of 5 stars$8.85-3.3%$25.60+189.3%+22.1%$499.44MN/A-4.2330Positive NewsCRMDCorMedix2.5328 of 5 stars$8.12-1.1%$15.80+94.6%+129.1%$492.70M$12.26M-10.0230Positive NewsVERVVerve Therapeutics2.7418 of 5 stars$5.56-7.6%$25.75+363.1%-52.0%$470.73M$24.40M-2.26110TERNTerns Pharmaceuticals3.9315 of 5 stars$5.54-4.0%$18.30+230.3%-8.6%$470.56M$1M-4.6940TBPHTheravance Biopharma2.1908 of 5 stars$9.52-0.7%$13.75+44.4%-19.7%$468.14M$63.19M-9.43359RNACCartesian Therapeutics2.704 of 5 stars$18.32-7.4%$42.86+133.9%-9.7%$465.60M$47.94M-0.3537PRTCPureTech Health1.9595 of 5 stars$19.10-2.1%$45.00+135.6%-24.8%$457.29M$3.33M0.00100Gap DownARCTArcturus Therapeutics2.8504 of 5 stars$16.58-2.6%$66.75+302.6%-42.8%$449.10M$142.47M-7.47180Positive NewsABVXABIVAX Société Anonyme2.3678 of 5 stars$7.02-1.4%$38.67+450.8%-31.7%$444.70MN/A0.0061Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Emergent BioSolutions Alternatives Astria Therapeutics Alternatives CorMedix Alternatives Verve Therapeutics Alternatives Terns Pharmaceuticals Alternatives Theravance Biopharma Alternatives Cartesian Therapeutics Alternatives PureTech Health Alternatives Arcturus Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PEPG) was last updated on 1/4/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
